Xeroderma pigmentosum is a definite cause of Huntington’s disease-like syndrome

Hector Garcia-Moreno, Hiva Fassihi, Robert P.E. Sarkany, Julie Phukan, Thomas Warner, Alan R. Lehmann & Paola Giunti

1Ataxia Centre, Department of Molecular Neuroscience, University College London, Institute of Neurology, London, WC1N 3BG, United Kingdom
2National Xeroderma Pigmentosum Service, St John’s Institute of Dermatology, Guy’s and St Thomas’ Foundation Trust, London, SE1 7EH, United Kingdom
3Neurology Department, Royal Free Hospital, London, NW3 2QG, United Kingdom
4Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom
5Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, BN1 9RQ, United Kingdom

Abstract

Xeroderma pigmentosum is characterized by cutaneous, ophthalmological, and neurological features. Although it is typical of childhood, late presentations can mimic different neurodegenerative conditions. We report two families presenting as Huntington’s disease-like syndromes. The first case (group G) presented with neuropsychiatric features, cognitive decline and chorea. Typical lentigines were only noticed after the neurological disease started. The second case (group B) presented adult-onset chorea and neuropsychiatric symptoms after an aggressive ocular melanoma. Xeroderma pigmentosum can manifest as a Huntington’s Disease-like syndrome. Classic dermatological and oncological features have to be investigated in choreic patients with negative genetic tests for Huntington’s disease-like phenotypes.
sun sensitivity since infancy, resulting in severe sunburn to minimal sun exposure.\(^4\) Lentigines in sun-exposed areas and multiple cutaneous tumors are also distinctive for the disease. Secondly, ocular surface pathology, eyelid damage, and ophthalmic neoplasms are also common. Neurological manifestations occur in 20–30% of cases,\(^4\) usually after the cutaneous signs. Cognitive impairment, cerebellar signs, sensorineural hearing loss, and sensorimotor axonal neuropathy have been reported.\(^6,9\) In advanced cases, movement disorders may appear.\(^7,8,10\)

There is noteworthy phenotypic variability among the different XP groups and within each group.\(^5,7\) Thus, XP can be misdiagnosed in the absence of early dermatological features, especially in late-onset neurodegenerative phenotypes. To our knowledge, we describe here the first XP-G and XP-B families whose main neurological features tightly resemble a Huntington’s disease-like (HD-like) phenotype.

**Patients and Methods**

Informed consent was obtained from both patients. This study was performed in accordance with protocols approved by the Research Ethics Committee of Guy’s and St Thomas’ Foundation Trust (12/LO/0325). The diagnostic techniques have been previously described.\(^5,11\) Pedigrees were designed using the CeGaT Pedigree Chart Designer tool\(^15\).

**Results**

**Case 1**

The first case was a 63-year-old lady who had suffered from sun sensitivity since childhood, with two episodes of severe sunburn. She had not received any prior neuropsychiatric treatments, including dopamine blocking or

---

**Figure 1.** A: case 1 pedigree (member order, age, phenotype/comments). The subjects with a dot are carriers for the mutation. B: case 2 pedigree (member order, age, phenotype/comments). The pedigree was altered to preserve anonymity.
depleting agents. First neurological symptoms appeared when she was 53, as mild short-term memory impairment, and loss of her standards of personal hygiene. Two years later, she complained of hearing loss and some hyperkinetic movements were noted. During the ensuing 5 years, she experienced progressive deterioration in neuropsychiatric symptoms with disinhibition, apathy and neglect of personal hygiene; as well as worsening of balance and involuntary movements, resulting in multiple falls. Subsequently, she was referred to a movement disorder specialist, who found she had generalized chorea and commenced a treatment with 7.5 mg olanzapine, with improvement of the hyperkinetic movements.

When assessed in our clinic, she was found to have extensive lentigines and hypopigmented macules at sun-exposed sites. She had photophobia, lagophthalmos, mild keratopathy and sunken eyes. Neurologically, she was disoriented and had poor executive function. She had a full range of external ocular movements, with nystagmus, slow initiation of saccades, and sluggish pupils. She showed pyramidal features in the lower limbs (weakness, hyperreflexia and Babinski’s sign) and cerebellar signs in the upper limbs (dysmetria and intentional tremor). The gait was broad-based with mild camptocormia and preserved arm swing. There was chorea in the fingers, as well as, neck and trunk dystonia. Her clinical status progressively declined with hallucinations, delusions, disrupted behavior and loss of independent gait (Video S1). She died at the age of 69, following a pulmonary thromboembolism.

Her parents came from the same village in Cyprus. The patient was the third of seven siblings. Two siblings presented sun sensitivity, lentigines, and developed cognitive impairment and slurred speech in their 50s. They died at the age of 62 and 59. The fourth sibling was a lady who showed pigmentary changes and lentigines, as well as slurred speech and cerebellar ataxia from her 50s. Later, she developed chorea and dementia. All the three affected siblings developed hearing impairment. The other siblings and the patient’s daughters were unaffected (Fig. 1A).

Her brain MRI (Fig. 2) showed nonspecific atrophy of the brain and cerebellum without involvement of the caudate nuclei. Nerve conduction studies were normal. Pure tone audiometry revealed bilateral sensorineural hearing loss. Three blood films for acanthocytes were negative, as well as lupus anticoagulant and anticardiolipin antibodies. An extensive battery of genetic tests yielded negative results, including: HD; familial prion disease (PRNP); HDL-2 (junctophilin-3); C9orf72 expansion; dentatorubral-pallidoluysian atrophy (DRPLA, atrophin-1); spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7, 12, and 17. Owing to the significant cutaneous involvement, the suspicion of XP was raised and an unscheduled DNA synthesis assay was performed. Her skin fibroblasts were defective for the NER system, showing less than 15% of repair activity after ultraviolet radiation. XP genes sequencing showed a homozygous single nucleotide substitution (c.869T>A) in exon 7 of the XP-G/ERCC5 gene. This is predicted to cause a single amino acid substitution (p.Ile290Asn) and has been previously reported as a pathogenic missense mutation.3 The patient was therefore diagnosed with late-onset XP-G. Her affected sister was homozygous for the same mutation. Two of the unaffected siblings were carriers.

**Case 2**

The second case was a 52-year-old patient who was easily sunburned since childhood, and had lentigines since the age of 2 years. Regarding previous pharmacological treatments, no prior dopamine antagonists were noted. A melanoma in the right corneal limbus was detected at the age of 22 and the first of multiple nonmelanoma cancers was diagnosed 7 years later. Due to a recurrence of the melanoma, an enucleation of the eye was performed at the age of 36 years old. Neurologically, the patient presented at the age of 17 with severe bilateral sensorineural hearing loss. On examination, the patient had dense lentigines and hypopigmented macules on sun-exposed sites such as the face, neck and arms. There were also numerous cherry angiomata at those sites. Choreic movements, with grimaces and emotional lability were noted. Despite normal tone and power throughout, pyramidal signs were found (brisk reflexes and bilateral Babinski’s sign). The upper limbs showed dysmetria and intentional tremor. There

---

**Figure 2.** T2-weighted image MRI from case 1.
## Table 1. Features of the main HD-like syndromes compared to XP cases

| Inheritance | Gene | Mutation | Ethnicity | Onset | Movement disorders | Cerebellar signs | Cognitive involvement | Psychiatric symptoms | Seizures | Other features | MRI |
|-------------|------|----------|-----------|--------|--------------------|------------------|----------------------|----------------------|----------|---------------|-----|
| AD          | TBP  | Expanded CAG/CAC | Caucasian, Asian | 3–75 y.o. | Chorea (20%) | ++ (>90%) | ++ (100%) | + | + (50%) | No peripheral nerve or muscle abnormality | Cerebellar atrophy. Rim enhancement of putamen |
| AD          | PRNP | Octapeptide repeat insertion | France, Netherlands | 20–45 y.o. | Chorea, rigidity | + | - | ++ (100%) | + | Myoclonus (young onset) | Mild cortical and subcortical atrophy. |
| AD          | JPH3 | Expanded GTC/CAG | Black South African | 20–30 y.o. | Dystonia > Chorea | ++ | ++ | ++ (100%) | + | Action-specific orofacial dystonia | Atrophy of caudate and cerebral hemispheres |
| AD          | ATN1 | Expanded CAG | Japan | 10–20 y. | Chorea | ++ | ++ | ++ (100%) | | Tongue protrusion and biting. | T2WI-hyperintense white matter lesions and PC atrophy |
| AD          | FTL  | Adenine insertion in exon 4 | France | 40 y.o. | Chorea | ++ | ++ | ++ (100%) | | Neuropathy. Amyotrophy. | T2*WI-hypointense signal in BG and thalamus |
| AR          | VPS13A | Various | Japan, French-Canadian | 20–30 y.o. | Chorea, dystonia, PD-like | - | ++ | - | Mild sun sensitivity, freckles. | Cerebellar, cortical and subcortical atrophy. |
| AR          | ERCC4 | Various | French, Japanese | 15–20 y. | Chorea | ++ | - | | | Sensorineural | T2WI, T2-weighted image MRI, PC, pontocerebellar |
| AR          | ERCC5 | p.Ile290Asn | Caucasian, Japan | 30–47 y.o. | Chorea | + | ++ | ++ (50%) | | Skin tumors. | T2*WI, T2*Echo gradient-weighted image MRI |
| AR          | ERCC3 | p.Phe99Ser, p.Arg425X | Greek Cypriot | >20 y. | Chorea | - | - | | | Ocular disease. SN hearing loss. | HD-like Phenotype in XP |
| AR          | ERCC3 | Early childhood | Caucasian/Caribbean | >50 y. | Chorea | - | - | | | Sun sensitivity, freckles, skin tumors. | SN hearing loss. |

AD, autosomal dominant; AR, autosomal recessive; TBP, TATA-box binding protein; PRNP, prion protein (PrP); JPH3, junctophilin-3; ATN1, atrophin-1; FTL, ferritin light chain; VPS13A, chorein; ERCC4, excision repair cross-complementing protein-4; ERCC5, excision repair cross-complementing protein-5; ERCC3, excision repair cross-complementing protein-3; y.o., years old; y., years; N/R, not reported; PD-like, Parkinson’s disease-like; -, not prominent; +, common; ++, very frequent; SN, sensorineural; T2WI, T2-weighted image MRI, PC, pontocerebellar; T2*WI, T2*Echo gradient-weighted image MRI; BG: Basal Ganglia.
was also some numbness in the right foot and a broad-based gait. One year later, the patient complained of neck pain spreading to the left arm. After several investigations, she was diagnosed with a left upper lobe lung neoplasm. The patient died at the age of 55, due to complications of metastatic lung cancer.

One of the patient’s siblings also had multiple skin tumors, early deafness and required enucleation of one eye due to melanoma (Fig. 1B).

The patient’s MRI showed diffuse cerebral and cerebellar atrophy. Genetic analysis revealed heterozygous mutations in the XP-B/ERCC3 gene (namely, c.296T>C, resulting in the missense mutation p.Phe99Ser; and c.1273C>T, producing the nonsense mutation p.Arg425X), both of which have been previously reported.5,11 Therefore, the diagnosis of XP-B was made at the age of 43. The affected sibling shared the same genotype.

Discussion

Both index cases exemplify the challenge of XP diagnosis in late-onset neurodegenerative phenotypes, especially in the presence of inconspicuous skin manifestations.

Neurological symptoms in XP patients can constitute a major source of disability and can carry higher rates of mortality in patients, compared to those without neurological involvement (37% vs. 29%).12 While strict photoprotection can prevent cutaneous and ophthalmological complications, there are no treatments to slow down the progression of the neurological disease. Neurologists should proactively investigate the presence of lentigines in sun-exposed areas (face, neck, hands . . .), a previous history of easy or severe sunburn, or previous skin cancers, even if the first cutaneous signs occurred in childhood.

Both cases fulfilled the criteria for HD-like syndromes13: presence of movement disorders consistent with HD, a negative genetic test for HD, the occurrence of cognitive impairment and/or behavioral disturbances, and a positive family history for analogous neurological disorders. HD-like syndromes are challenging entities, since a definite genetic diagnosis is reached in less than 3% of cases.14 Previously, the principal identified diseases were C9orf72 expansion, SCA 17, HDL-1 (mutations in PRNP) and HDL-2 (mutations in junctophilin-3). Conditions such as DRPLA, neuroferritinopathy or chorea-akanthocytosis can also present as HD-like disorders. The main characteristics of these conditions are summarized in Table 1.11,13–20

We have presented here the occurrence of chorea and cognitive impairment in patients with mutations in different genes of the NER pathway (ERCC5 and ERCC3). In a recent report by Carré et al.,15 two XP-F patients (with mutations in the ERCC4 gene) with chorea and cerebellar ataxia were also described. Consequently, we reinforce the notion that XP should be included in the differential diagnosis of HD-like syndromes. The suspicion of XP should be raised if there is a history of skin disorder, even as mild as in the first presented case, and alternative genetic testing is negative.

The cases in this report illustrate novel pathophysiological mechanisms. Since a DNA repair disorder can mimic HD, the NER pathway might be of importance for both conditions. Apart from its role against photo-products, the NER system also repairs the damage caused by inner sources, such as oxidative damage.3 Due to the NER system impairment, both nuclear and mitochondrial DNA (mtDNA) can accumulate mutations. It is known that mtDNA damage and mitochondrial dysfunction occur in HD.2 Therefore, NER disruption might contribute to the mitochondrial damage and neuronal loss in HD. Moreover, XP-B and XPG are components of the transcription factor IIH (TFIIH)21,22 which participates in transcription processes. Dysregulation of this mechanism might contribute to the neurodegeneration in XP.

Our cases emphasize the occurrence of hyperkinetic abnormal movements in DNA repair disorders. Subtle dystonia or tremor is often apparent in XP patients, even in those cases without overt neurological manifestations (PG observation). Recent reports have illustrated the relation between cerebellar atrophy and different movement disorders in mitochondrial conditions23 and HD.24 It is unclear whether the NER pathway could be particularly relevant for basal ganglia metabolism or whether the hyperkinetic movement disorders are a consequence of the cerebellar dysfunction: further studies are needed to elucidate the underlying pathogenesis.

Acknowledgments

The authors thank the study participants and their relatives, as well as Arron Cook and Michael Parkinson for the review of the manuscript. The National XP Clinic in the United Kingdom is funded by the National Health Service England Highly Specialized Services. This work was also supported by the UK National Institute for Health Research Biomedical Research Centre based at Guy’s and St Thomas’ Foundation Trust and King’s College London. PG and HGM work at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health’s NIHR Biomedical Research Centers funding scheme, and receives support from the NIHR Clinical Research Network (CRN).
Author’s Contribution

Hector Garcia-Moreno: Research Project: B. Organization, C. Execution. Manuscript: A. Writing of the first draft, B. Review and Critique. Hiva Fassihi: Research Project: B. Organization, C. Execution. Manuscript: B. Review and Critique. Robert P.E. Sarkany: Research Project: B. Organization, C. Execution. Manuscript: B. Review and Critique. Julie Phukan: Research Project: B. Organization. Manuscript: A. Writing of the first draft, Prof Thomas Warner: Research Project: B. Organization. Manuscript: B. Review and Critique. Prof Alan R. Lehmann: Research Project: B. Organization. Manuscript: B. Review and Critique. Paola Giunti: Research project: B. Organization, C. Execution. Manuscript: B. Review and Critique. Warner: Research Project: B. Organization. Manuscript: B. Review and Critique. Hiva Fassihi: Research Project: B. Organization, C. Execution. Manuscript: A. Writing of the first draft, HGM work at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health’s NIHR Biomedical Research Centers funding scheme, and receives support from the NIHR Clinical Research Network (CRN). The other authors have nothing to report.

Conflict of Interest

HGM has received financial support from Medical Research Council, and from Actelion Pharmaceuticals UK for travel to scientific symposiums. TW have received funding from Britannia Pharmaceuticals, Medical Research Council, Reta Lila Weston Medical Trust and Corticobasal Degeneration Solutions Inc. PG has received financial support from Actelion Pharmaceuticals Inc, Pfizer, Reata Pharmaceuticals Inc, Ataxia UK and Medical Research Council. PG and HGM work at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health’s NIHR Biomedical Research Centers funding scheme, and receives support from the NIHR Clinical Research Network (CRN). The other authors have nothing to report.

REFERENCES

1. Rass U, Ahel I, West SC. Defective DNA repair and neurodegenerative disease. Cell 2007;130:991–1004.
2. Jeppesen DK, Bohr VA, Stevnsner T. DNA repair deficiency in neurodegeneration. Prog Neurobiol 2011;94:166–200.
3. Rao KS. Mechanisms of disease: DNA repair defects and neurological disease. Nat Clin Pract Neurol 2007;3:162–172.
4. Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis 2011;6:70.
5. Fassihi H, Sethi M, Fawcett H, et al. Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. Proc Natl Acad Sci USA 2016;113:E1236–E1245.
6. Mimaki T, Itoh N, Abe J, et al. Neurological manifestations in xeroderma pigmentosum. Ann Neurol 1986;20:70–75.
7. Anttinen A, Koulu L, Nikoskelainen E, et al. Neurological symptoms and natural course of xeroderma pigmentosum. Brain 2008;131:1979–1989.
8. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241–250.
9. Sethi M, Lehmann AR, Fawcett H, et al. Patients with Xeroderma Pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions. Br J Dermatol 2013;169:1279–1287.
10. Adamec D, Xie J, Poisson A, et al. Xeroderma pigmentosum: a rare cause of chorea. Rev Neurol (Paris) 2011;167:837–840.
11. Oh KS, Khan SG, Jaspers NG, et al. Phenotypic heterogeneity in the XBP DNA helicase gene (ERCC3): xeroderma Pigmentosum without and with Cockayne syndrome. Hum Mutat 2006;27:1092–1103.
12. Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in Xeroderma Pigmentosum: long term follow-up characterizes the role of DNA repair. J Med Genet 2011;48:168–176.
13. Wild EJ, Tabrizi SJ. Huntington’s disease phenocopy syndromes. Curr Opin Neurol 2007;20:681–687.
14. Wild EJ, Mudanohwo EE, Sweeney MG, et al. Huntington’s disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008;23:716–720.
15. Carré G, Marelli C, Anheim M, et al. Xeroderma pigmentosum complementation group F: a rare cause of cerebellar ataxia with chorea. J Neurol Sci 2017;376:198–201.
16. Moore RC, Xiang F, Monaghan J, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001;69:1385–1388.
17. Sunami Y, Koide R, Arai N, et al. Radiologic and neuropathologic findings in patients in a family with dentatorubral-pallidolysian atrophy. AJNR Am J Neuroradiol 2011;32:109–114.
18. Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007;130:110–119.
19. Jung HH, Danek A, Walker RH. Neuroacanthocytosis Syndromes. Orphanet J Rare Dis 2011;6:68.
20. Hensman Moss DJ, Poulter M, Beck J, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 2014;82:292–299.
21. Compe E, Egly JM. Nucleotide excision repair and transcriptional regulation: TFIIH and beyond. Annu Rev Biochem 2016;85:265–290.
22. Ito S, Kuraoka I, Chymkowitch P, et al. XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for cockayne syndrome in XP-G/CS Patients. Mol Cell 2007;26:231–243.
23. Schreglmann SR, Riederer F, Galovic M, et al. Movement disorders in genetically confirmed mitochondrial disease.
and the putative role of the cerebellum. Mov Disord 2017; https://doi.org/10.1002/mds.27174.

24. Rees EM, Farmer R, Cole JH, et al. Cerebellar abnormalities in huntington’s disease: a role in motor and psychiatric impairment? Mov Disord 2014;29:1648–1654.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Video S1. Segment 1. Dystonic posture of the neck (with predominant laterocaput to the left and elevation of right shoulder) and the trunk was observed. The patient showed frequent blinking and choreic movements in the oromandibular area and the four limbs. In addition, lentigines in the face, the neck and hands are visible. Segment 2. The patient needed constant bilateral support of an accompanying person due to her imbalance. It is remarkable the broad-based gait, with small steps and difficulty in turning, as well as the stoop position.